Drug & Supplement Interactions

Antineoplastons + Pneumococcal polyvalent

Brand names of Pneumococcal polyvalent

  • Pneumovax 23
  • Pnu-Imune 23

Medically reviewed by

Also reviewed by the HelloPharmacist Editorial Team

Updated July 2026Details about this page

AI is used only to summarize verified clinical information, never the open internet. Our AI policy

The Bottom Line No Known Interaction

We found no known interaction between Antineoplastons and Pneumococcal polyvalent in our sources.

This also applies to Pneumovax 23 and Pnu-Imune 23, brand names of pneumococcal polyvalent.

See the Full Interaction Report

Ask a Question About This Combination

Ask in your own words about taking Antineoplastons with Pneumococcal polyvalent. The answer comes from this page’s own records.

Try:

AI answers from this page’s interaction records and our own drug and supplement information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist. How we use AI

Interaction Report

Antineoplastons and Pneumococcal polyvalent Interaction Check

No Known Interaction Found

We did not find a documented interaction between Pneumococcal polyvalent and Antineoplastons in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.

How We Checked

Why No Interaction Is Listed for Pneumococcal polyvalent

Neither one has a record. Our interaction database holds no record for Antineoplastons with any drug, and none for Pneumococcal polyvalent with any supplement, so this rests on missing data, not on a study that found nothing.

Still wondering about combining Antineoplastons and Pneumococcal polyvalent? Ask Dr. Brian Staiger, PharmD, BCPS directly ›
Know someone taking this combination? Share
What to Watch For

What Antineoplastons Itself Has Been Linked To

  • This is not an interaction: nothing below involves Pneumococcal polyvalent.
  • It is the side-effect record for Antineoplastons on its own, from the licensed Natural Medicines monograph.
  • If something new turns up after you add Antineoplastons, this list is the first place to look.
  • 3 entries are worth acting on rather than waiting out, marked below.
  • Low blood sugar / Low potassium Worth Acting On Additional detail

    Adverse effects to antineoplastons have been reported in several small clinical studies. It is not clear how common these reactions are, or if they occur more frequently than with placebo. Since many patients taking antineoplastons have been diagnosed with serious illnesses, such as advanced cancers, it is not clear if these effects resulted from the illnesses themselves or were caused by antineoplastons.

    Source: , the clinical database we license.

    5 references cited
    1. 20101. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
    2. 25604. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249. PubMed
    3. 25620. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
    4. 25621. Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up. Drugs Exp Clin Res 1987;13 Suppl 1:1-11.
    5. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed
  • An irregular heartbeat / Chest pain / Raised blood pressure Worth Acting On Additional detail

    Intravenously, antineoplaston A5 has been associated with palpitations at doses up to 153 mg/kg daily. A 71 year-old male bladder cancer patient experienced chest pressure and irregular heartbeat after receiving intravenous antineoplaston A5 58 mg/kg/day for 5 days. Use of intravenous antineoplaston AS2-1, up to 160 mg/kg daily for over 2 years, has been associated with mild hypertension.

    Source: , the clinical database we license.

    5 references cited
    1. 25608. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 1987;13 Suppl 1:37-43.
    2. 25622. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 1987;13 Suppl 1:37-43.
    3. 25604. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249. PubMed
    4. 25619. Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:25-35.
    5. 25607. Burzynski SR, Kubove E. Phase I clinical studies of antineoplaston A3 injections. Drugs Exp Clin Res 1987;13 Suppl 1:17-29.
  • Anemia Worth Acting On Additional detail

    Orally and intravenously, decreased bone marrow activity has been reported for patients treated with chemotherapy along with antineoplaston A10 or antineoplaston AS2-1; however, this effect has not been observed for patients treated with these antineoplastons without chemotherapy.

    Intravenously, antineoplastons A10 and AS2-1 have been associated with anemia and lowered white blood cell counts in patients with brain t…

    Source: , the clinical database we license.

    6 references cited
    1. 20101. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
    2. 25604. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249. PubMed
    3. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed
    4. 25611. Burzynski SR, Weaver RA, Janicki T, et al. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1. Integr Cancer Ther 2005;4(2):168-177. PubMed
    5. 99814. Burzynski SR, Janicki TJ, Weaver RA, Burzynski B. Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integr Cancer Ther. 2006 Mar;5(1):40-7. PubMed
    6. 25623. Kumabe T, Tsuda H, Uchida M, et al. Antineoplaston treatment for advanced hepatocellular carcinoma. Oncol Rep 1998;5(6):1363-1367. PubMed
  • Ringing in the ears Additional detail

    Orally and intravenously, headache, fatigue, sleepiness, ringing in the ears, and numbness have been reported for patients treated with antineoplastons A10 and AS2-1. Dizziness has also been noted for some patients treated with oral antineoplaston A10 or intravenous antineoplaston A3.

    Source: , the clinical database we license.

    6 references cited
    1. 25593. Buckner JC, Malkin MG, Reed E, et al. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 1999;74(2):137-145. PubMed
    2. 25601. Burzynski SR, Conde AB, Peters A, et al. A retrospective study of antineoplastons A10 and AS2-1 in primary brain tumors. Clin Drug Invest 1999;18(1):1-10.
    3. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed
    4. 25610. Burzynski SR, Weaver RA, Lewy RI, et al. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report. Drugs R D 2004;5(6):315-326. PubMed
    5. 25620. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
    6. 20101. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
  • Chills / Sore throat Additional detail

    Recorded for Antineoplastons in the same Natural Medicines adverse-effect record shown under Low blood sugar / Low potassium above.

  • Bloating or gas Additional detail

    Orally, nausea, vomiting, upset stomach, abdominal pain, and excessive flatulence has been reported for patients with neoplastic disease treated with antineoplaston A10 100-149 mg/kg/day for up to 149 days.

    Source: , the clinical database we license.

    2 references cited
    1. 20101. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
    2. 25620. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.

Showing the 10 most notable of 25 recorded effects — ranked by how unusual each one is across medicines generally, with serious effects weighted up.

Everything above comes from the Natural Medicines adverse-effect record for Antineoplastons — expand a row for the licensed statement it rests on. We haven’t matched Pneumococcal polyvalent to its FDA label in our system yet, so we can’t compare its own side-effect list here — the leaflet that comes with your prescription is the authoritative list for Pneumococcal polyvalent.

If You Decide to Take Both
  • Add one new thing at a time, and note the date you started it.
  • A start date turns “I’ve been feeling off” into something a pharmacist can work with.
  • Do not stop a prescribed medicine on your own.
  • Check with your pharmacist or doctor before changing any medicine or supplement, especially if you take several or have an ongoing health condition.
Alternatives for the Same Use

Other Supplements for the Same Uses as Antineoplastons, and How They Mix With Pneumococcal polyvalent

Choosing a supplement while you take Pneumococcal polyvalent? Pick what you use Antineoplastons for to see other options studied for it, and whether each has a documented interaction with Pneumococcal polyvalent.

What do you take Antineoplastons for?

For Prostate Cancer

None of them has a documented interaction with Pneumococcal polyvalent.

3 other supplements have at least some evidence of a benefit for prostate cancer. Antineoplastons itself is graded for it.

  • Lycopene Graded No Known Interaction
  • Strontium Graded No Known Interaction
  • Sulforaphane Graded No Known Interaction

For Colorectal Cancer

None of them has a documented interaction with Pneumococcal polyvalent.

2 other supplements have at least some evidence of a benefit for colorectal cancer. Antineoplastons itself is graded for it.

The grades come from the Natural Medicines database and describe the research so far, not a recommendation, and none of these supplements replaces a prescribed medicine.

Supplement

About Antineoplastons

Antineoplastons are synthetic peptide and amino acid compounds promoted as an alternative cancer treatment, but they are not approved by the FDA and high-quality clinical evidence supporting their effectiveness is lacking. Most studies have been conducted by their developer and have not been independently confirmed. If you are considering them, talk with your oncologist first, and never replace proven cancer treatment with an unproven one.

Full Antineoplastons guide: uses, dosage, safety and every interaction
Safety at a Glance

How Antineoplastons Is Rated

  • Antineoplastons Overall

    Use caution

    Not FDA-approved; effectiveness is unproven and side effects can be serious, especially at high doses.

  • Pregnancy

    Avoid

    There is no reliable safety data, so use during pregnancy should be avoided.

  • Breastfeeding

    Avoid

    Safety while breastfeeding is unknown, so it should be avoided.

More to Explore

More Pairs and Interactions to Check

Keep Checking

Other Drugs & Antineoplastons

Browse every other medication we’ve checked against Antineoplastons — both the ones with a known interaction and the ones without. Select any drug for the full detail.

0Major
0Moderate
0Minor
2,829No known interaction
No Interaction 2,829 drugs checked — show the list
How Much People Look This Up

Where Antineoplastons and Pneumococcal polyvalent Sit Against Everything Else

Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.

Supplement Antineoplastons
Steady interest

#1,279 of 1,458 supplements looked up here in the last 7 days

29 days ago today
Medication Pneumococcal polyvalent
Top 25%

#560 of 2,830 medications looked up here in the last 7 days

29 days ago today

A rank of lookups on this site, not of how often either one is used. It counts every visit, automated ones included, and identifies no one.

Questions and Sources

Common Questions and Where This Comes From

Pharmacist Counseling Corner

Taking Antineoplastons and Pneumococcal polyvalent Together: Common Questions

Can you take Antineoplastons with Pneumococcal polyvalent?
We do not list a known interaction between Antineoplastons and Pneumococcal polyvalent. That does not guarantee the combination is risk-free, so confirm with your pharmacist or doctor — especially if you take other medications or have a health condition.
Can you take Antineoplastons with Pneumovax 23?
Pneumovax 23 is a brand name of pneumococcal polyvalent, and so is Pnu-Imune 23, so the answer is the same as for pneumococcal polyvalent. We do not list a known interaction between Antineoplastons and Pneumococcal polyvalent. Everything on this page applies to Pneumovax 23 too.
Do other supplements studied for prostate cancer interact with Pneumococcal polyvalent?
None of the 3 other supplements the Natural Medicines database grades as having some evidence of a benefit for prostate cancer has a documented interaction with Pneumococcal polyvalent. A grade is the research so far, not a recommendation, and no known interaction is not proof of safety; ask your pharmacist before adding one.

Written and reviewed by the HelloPharmacist Editorial Team. Our editorial policy

Evidence & Sources

References Cited on This Page

The 15 references the cards above cite, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

Show the 15 references
  1. 20101. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
  2. 25593. Buckner JC, Malkin MG, Reed E, et al. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 1999;74(2):137-145. PubMed
  3. 25601. Burzynski SR, Conde AB, Peters A, et al. A retrospective study of antineoplastons A10 and AS2-1 in primary brain tumors. Clin Drug Invest 1999;18(1):1-10.
  4. 25603. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed
  5. 25604. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249. PubMed
  6. 25607. Burzynski SR, Kubove E. Phase I clinical studies of antineoplaston A3 injections. Drugs Exp Clin Res 1987;13 Suppl 1:17-29.
  7. 25608. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 1987;13 Suppl 1:37-43.
  8. 25610. Burzynski SR, Weaver RA, Lewy RI, et al. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report. Drugs R D 2004;5(6):315-326. PubMed
  9. 25611. Burzynski SR, Weaver RA, Janicki T, et al. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1. Integr Cancer Ther 2005;4(2):168-177. PubMed
  10. 25619. Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:25-35.
  11. 25620. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
  12. 25621. Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up. Drugs Exp Clin Res 1987;13 Suppl 1:1-11.
  13. 25622. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 1987;13 Suppl 1:37-43.
  14. 25623. Kumabe T, Tsuda H, Uchida M, et al. Antineoplaston treatment for advanced hepatocellular carcinoma. Oncol Rep 1998;5(6):1363-1367. PubMed
  15. 99814. Burzynski SR, Janicki TJ, Weaver RA, Burzynski B. Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integr Cancer Ther. 2006 Mar;5(1):40-7. PubMed

All 20 references behind our Antineoplastons records are listed in the Antineoplastons guide.

Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is reviewed by the HelloPharmacist Editorial Team. See our data sources and editorial standards.

Where Does Our Data Come From?
  • Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
  • Citation library: 105,612 references behind our interaction content, 67,053 of them resolved to verified PubMed/DOI sources. See the references behind this page ↓
  • Freshness: we automatically re-check this combination every week — this pair was last verified November 15, 2026. The Antineoplastons and Pneumococcal polyvalent records this page draws on were last updated July 10, 2026.
Data structure & sourcing designed and verified by .
Rating Key

What Our Interaction Ratings Mean

No interaction is on record for this pair. The other supplements and medicines on this page carry a severity rating: how serious an interaction between them is.

See what each severity means

Severity: How Serious Is It?

How clinically significant the interaction is: how much it could affect your health or your treatment.

  • MajorClinically significant. Best to avoid the combination, or use only under close professional supervision.
  • ModerateBe cautious. The combination may call for monitoring, timing changes, or a dose adjustment.
  • MinorLimited clinical concern, but still worth being aware of and mentioning to your pharmacist.
  • No Known InteractionNo documented interaction in our sources.

Still Have a Question About Antineoplastons and Pneumococcal polyvalent?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.